GSK Rebuts Teva’s ‘Doomsday Scenario’ On Skinny-Label Generics

Originator Urges US Supreme Court To Reject Review Of Indication Carve-Out Lawsuit

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.